Medable alternatives for teams running DCTs outside top 50 pharma
Medable makes sense if you're top 50 pharma running a late-stage DCT. Outside that, the pricing and implementation model rarely fits. WeGuide gives smaller teams the same DCT building blocks, eCOA, eConsent, wearables, and a whitelabel participant app, usually live within six weeks.
No pressure, no hard sell. A 30-minute walkthrough with a research colleague who's built platforms like yours.
.png)
Used by leading research and medical institutes.
%201.avif)
Why research teams look for a Medable alternative
Medable's product and commercial model were both designed around a specific customer: top 50 pharma sponsors running decentralised Phase II to IV trials. The eCOA depth, the eConsent workflows, the patient facing app suite, and the FDA submission track record all reflect that focus. For that customer, the fit is real.
For everyone else, the gap shows up quickly. Academic medical centres don't have Medable-scale implementation budgets. Mid-market CROs can't justify enterprise pricing for a 200-participant study. Investigator-led research teams don't have the programme management capacity to run a Medable engagement. And use cases outside DCTs, like registries, population health, employee wellbeing, and citizen science, sit entirely outside Medable's product scope.
.png)
Key differences between WeGuide and Medable
For teams that need DCT architecture but don't fit Medable's enterprise profile, here's what changes when you move to WeGuide.
.png)
Mid market accessibility
.png)
Broader use cases beyond DCTs
.png)
Deploy in weeks, not enterprise cycles
Full comparison: WeGuide vs Medable
.png)
Top alternatives to Medable in 2026
Here's the shortlist of decentralised trial platforms most teams evaluate when they're looking at alternatives to Medable.
.png){kind=small}
All-in-one platform
WeGuide combines eCOA, eConsent, data collection, and telehealth in a single platform with whitelabel apps under your own brand.
.png){kind=icon}
eConsent
.png)
.png){kind=icon}
Screening
.svg)
.svg)
.png){kind=icon}
Data collection
.svg)
.png){kind=icon}
Telehealth
.png)
.png)
.png)
%20(1)%20(1)%20(1).png)
%20(1).png)
.png)
.png)
Continuous engagement, not once-off surveys
Push notifications, educational content delivery, gamification, and a study companion that guides participants through the protocol. This is the difference between collecting data when a participant remembers and collecting data on schedule because the app is genuinely useful to them. The BRACE Trial achieved 90% adherence across 6,000 participants in five countries using this architecture. See WeGuide’s patient education module →
Push notifications and reminders
Study companion
Educational content and gamification
Mobile multimodal collection
Capture the full picture of a participant's experience through forms, video, pathology, and passive sensor data all in the same app.
Forms
.svg){kind=icon}
Video
.svg){kind=icon}
Pathology
.svg){kind=icon}
Sensors
.png)
%20(1).png)
.png)
%20(1).png)
.png)
%20(1).png)
.png)
Whitelabel: your study, your brand
WeGuide ships native iOS and Android apps fully branded under your organisation's name and identity. The app becomes the study's home for the participant, which is a big part of why our studies average 94% adherence.
.svg){kind=icon}
Your brand end-to-end
.svg){kind=icon}
App store distribution
.svg){kind=icon}
Multilingual out of the box.
Where WeGuide goes further
For teams that need the clinical layer without the rest of the Vault platform, here's what changes when you move from Veeva Clinical to WeGuide.
Mid market accessibility
.svg)
Broader use cases beyond DCTs
Deploy in weeks, not enterprise cycles
.svg)
Whitelabel mobile apps under your brand
.svg)
Native wearable integration
.png)
Australian data residency and TGA certification
Built for regulated research
Every WeGuide study runs on our managed infrastructure. Your IT team doesn't patch servers, manage backups, or run disaster recovery drills.
.png){kind=small}
TGA Certified
.png){kind=small}
ISO 27001
.png){kind=small}
Data Hosted in Australia
.png){kind=small}
GDPR Compliant
Biometric Security
.png){kind=small}
256-bit AES Encryption
Faster
Your own platform ready in weeks and changes are made in minutes
Adherence Rates
High patient engagement and better quality data
Cost Saving
Reduce financial and technology risk when creating a secure health app
Patients Impacted
With our ease of use and roll out, our apps have engaged 200k+ users
Where Medable excels
Deep pharma sponsor relationships. Medable has been running decentralised trials for top-50 pharma sponsors for years. That track record and those relationships create trust at the enterprise level that newer platforms have to earn. If you're a pharma sponsor whose therapeutic area team has already worked with Medable, there's real value in that continuity.
Comprehensive eCOA, eConsent, and patient-facing app suite. Medable has invested heavily in the decentralised trial stack. The eCOA library is deep, the eConsent workflows are regulatory mature, and the patient-facing app experience is polished. For enterprise DCTs, this is a capable platform.
Strong FDA submission experience. Medable has a multi-year track record of FDA-facing submissions with data sourced from its platform. That regulatory maturity matters for sponsors running late stage trials with direct FDA interaction.
Industry leading knowledge centre. Honestly, Medable's knowledge centre is one of the best educational resources in the DCT space. We use it as a reference point ourselves. If you're evaluating DCT concepts and vendor-agnostic best practices, it's a genuine asset to the industry.
If your study is a top 50 pharma late stage decentralised trial with enterprise budget and an experienced programme team, Medable is a defensible choice. We'd rather say that honestly than oversell what WeGuide does.
WeGuide and Medable can coexist
If your enterprise pharma portfolio already runs Medable for late stage decentralised trials, you don't have to rip that out to use WeGuide for your mid-market studies, registries, or engagement programmes. Our Integration Engine connects through APIs, so teams can run hybrid portfolios where each platform covers the studies it's best suited to.
How the switch works
For teams that are ready to move beyond Medable for specific studies or run WeGuide alongside it, here's how onboarding typically plays out.
Discovery Call
A 30-minute conversation with one of our research delivery team. We look at your protocol, your current setup, and what's blocking you. No sales pitch.
Study Configuration
Our team works alongside yours to configure the study in WeGuide. Typical timeline: two to four weeks.
.svg)
Participant Onboarding
The whitelabel app goes live. Your research coordinators invite participants, who download the app under your organisation's brand. eCOA instruments, consent flows, and engagement templates are ready.
Ongoing Support
You get a named research delivery contact, not a ticketing queue. We stay involved for the life of the study.
.png)
.png)
.png)
.png)
Case studies: research teams that run DCTs at mid market pace
BRACE Trial (Murdoch Children's Research Institute)
Murdoch Children's Research Institute. A global randomised controlled trial studying whether the BCG vaccine could reduce COVID-19 symptom severity. Launched across five countries with 6,000+ participants in six weeks during the pandemic. Adherence exceeded 90%. The study needed decentralised architecture but couldn't absorb an enterprise implementation timeline.
GenV (Generation Victoria)
A population health study tracking more than 100,000 Victorian families from birth. Longitudinal registry work at this scale sits outside Medable's DCT focus. The whitelabel family-facing app is the reason retention has held across multiple years.
INHERIT
An employee wellbeing deployment across a global workforce, using WeGuide's platform for participant reported outcomes, engagement content, and population health analytics. Completely outside enterprise DCT software scope, and the kind of programme that shows what a broader patient engagement platform enables.
%201.avif)
Questions
Straight answers on how WeGuide compares to Medable, what migration looks like, and when Medable is the right call.
Contact usIs WeGuide a full replacement for Medable?
For decentralised trials run by top 50 pharma sponsors, Medable's enterprise depth and FDA submission track record are genuinely hard to match, and we'll tell you that honestly. WeGuide is the right choice when you're a mid market sponsor, academic CRO, research institution, or digital health programme that needs the same DCT architecture (eCOA, eConsent, telehealth, wearables, whitelabel app) at a pace and price point that matches your research scope. Many of the teams we work with evaluated Medable first, concluded it wasn't the right fit for their mid-market study, and chose WeGuide for the same protocol.
Does WeGuide have an eCOA product like Medable?
Yes. WeGuide's eCOA is integrated into the Form Builder with a library of 200+ validated instruments, and it runs inside the same whitelabel app participants use for the rest of the study. The main architectural difference is that WeGuide's eCOA is part of a single integrated participant experience rather than sitting alongside a separate eConsent or engagement module. For mid market DCTs, that integration is often more valuable than specialist depth.
Does WeGuide support hybrid and decentralised trials?
Yes. Decentralised trial architecture is a core WeGuide use case. Telehealth, eConsent, remote monitoring, eCOA, whitelabel participant apps, wearables, and engagement are all built in. The BRACE Trial is a good example of what a rapid-deploy decentralised trial looks like on our platform: 6,000+ participants across five countries in six weeks.
How does WeGuide's knowledge centre compare to Medable's?
Medable's knowledge centre is genuinely excellent, and we'll happily recommend it as a reference for DCT concepts. WeGuide's strength is different. We publish case studies, platform documentation, and a research focused blog, and our real investment goes into working alongside research teams during study setup and delivery. The knowledge centre comparison is probably the one area where Medable has a clear edge, and we're comfortable saying that.
How do Medable and WeGuide compare on FDA facing submissions?
Both platforms are 21 CFR Part 11 ready. Medable has a longer FDA submission track record because of its pharma sponsor base. WeGuide adds TGA Class I medical device certification, ISO 27001, HIPAA, GDPR, and Australian data residency, which matters for APAC and globally distributed studies. For mid-market FDA facing work, WeGuide's compliance posture is appropriate. For enterprise late stage Phase III submissions under significant FDA scrutiny, a longer sponsor precedent may weigh in Medable's favour.
How does pricing compare?
Medable is enterprise custom quoted, typically with six figure minimums for a single study. WeGuide is project based and scales to the study's actual complexity, with every module included in the core licence. For mid market sponsors, academic research, and investigator-led studies, WeGuide is typically significantly less expensive, and the implementation cost is lower because you don't need a dedicated enterprise programme team.
Compare WeGuide to other clinical trial platforms
Eleven more honest platform comparisons, from academic EDC to enterprise pharma.
.png){kind=small}
Veeva Vault Clinical
Life sciences cloud
Thread Research
Virtual CRO + software
Clario
eCOA specialist
Oracle Clinical
Clinical One & InForm
.png){kind=small}
OpenClinica
Open-source EDC
.png){kind=small}
Medable
DCT for top-50 pharma
.png){kind=small}
IQVIA
Full-service CRO
Florence Healthcare
Site-side workflow
Science 37
Open-source EDC
obviohealth
Virtual site service
Medidata Rave
Enterprise pharma stack
REDCap
Data Collection
Never miss an update
Get all the latest news, blog posts and product updates from WeGuide, delivered directly to your inbox. We'll rarely send more than one email a month.
By clicking Organise a demo, you're confirming that we can contact you to set up a demonstration.
Certified and Compliant by Leading Standards
